滋阴清热方对阴虚内热证SLE白细胞基因及蛋白表达谱的动态影响
|
摘要
研究背景
系统性红斑狼疮(systemic lupus erythematosus，SLE)作为一种严重危害健康的自身免疫性疾病，其病因、发病机制尚未完全阐明，治疗至今仍是世界难题。目前西医仍主要用糖皮质激素和免疫抑制剂治疗，长期应用会带来明显的毒副作用。临床实践证明中西医结合治疗SLE临床疗效突出，可减少药物的毒副作用，提高SLE患者的生存质量。阴虚内热是SLE的基本证型，滋阴清热法是治疗SLE基本法则。现代研究认为SLE的发生是由多基因共同作用的结果。研究SLE基因调控网络和蛋白质相互作用网络的动态变化将有助于我们对SLE发病的深入了解。
目的
观察滋阴清热方治疗阴虚内热证SLE的疗效，研究SLE患者治疗前、中(治疗6周)、后(治疗12周)外周血单核细胞(peripheral blood mononuclear cell，PBMC)基因及蛋白表达谱的动态改变，了解阴虚内热证SLE患者基因及蛋白表达模式与正常人间的异同，从基因及蛋白水平探讨中医药治疗机理，为构建中医药治疗SLE的基因与蛋白表达谱研究方法与平台打下基础。
方法
1．研究对象
女性阴虚内热证SLE病例来自2005年11月至2006年11月在广东省中医院门诊就诊的确诊病人，轻、中度活动(5≤SLEDAI≥25分)，如使用了糖皮质激素，则维持量为10～25mg／日，三个月内不加量，如使用过非甾体抗炎药则需停药一周以上，如使用过其它免疫抑制剂则需停药半年以上。健康对照组来自于广州中医药大学健康大学生和健康志愿者，共15例，均为女性。治疗组总共纳入18例，其中退出2例，失访1例，有效病例共15例，平均年龄：31.60±9.37；健康对照组平均年龄：28.4±6.50。两组年龄经两样本t检验，方差齐性(P=0.098)，差异无统计学意义(P=0.289)。
2．治疗与疗效观察
入选病例用滋阴清热方制成胶囊，每次5粒，每日3次口服治疗3个月，每两周进行中医症候积分评估，并在中药治疗前、治疗6周、治疗12周时评定活动度积分，检测患者血清补体C_3、C_4水平、抗核抗体(ANA)、抗双链DNA抗体(Ds-DNA)、血常规、尿常规等指标，提取PBMC总RNA和总蛋白质，-70℃保存备用，将完成3次观察的合格病例的样品进行基因芯片与蛋白芯片的检测。所有病例均按病例资料收集要求与规范详细填写《病例观察报告表》。
3．基因芯片实验与分析方法
人类基因表达谱芯片由微芯生物公司采用cDNA直接点样生产，共有8064个基因点，采用Cy3单荧光标记探针，数据经标准化校正，计算基因表达量在实验组和对照组间的比值(Ratio)，按Ratio大于2或小于0.5作为表达差异的显著性标准。运用国际通用的GeneCluster 2软件对标准化后数据进行SOMs(self-organizing maps；自组图)分析、功能分类分析和聚类分析。
4．蛋白芯片实验与分析方法
采用表面加强激光解吸电离-飞行时间质谱(SELDI)方法建立SLE患者治疗前、治疗6周、治疗12周以及正常对照组PBMC蛋白质表达数据，利用浙江大学肿瘤研究所余捷凯等研究设计的ZUCIPDAS软件包找出蛋白质荷峰，建立判别模型，采用基因芯片表达数据库与Expasy蛋白数据库交连比对分析方法初步确定蛋白质荷峰的可能名称与功能。
结果
1．糖皮质激素配合滋阴清热方治疗可以较快缓解阴虚内热证SLE患者病情，改善自觉症状，SLEDAI积分、中医症候积分治疗后显著下降，C_3、C_4水平上升，患者病情有明显改善。中医症候积分与SLEDAI积分呈正相关，提示中医症候评分可以较客观地综合反映患者的病情。
2．经归一化等数据处理后得到2946个基因表达数据。对其中至少三次独立实验处理过程中存在明显的表达差异的数据进行自组图分析分为25类共167个基因，3次表达经重复测量数据的方差分析，差异有显著性意义(P=0.000)，其中有20个基因前后比较差异有统计学意义(P＜0.05)：其中人免疫球蛋白K链c区(IGKC)基因，治疗后下调，低于正常人，其余19个基因(Arp2、ARCN1、CRY2、DAF、DPYSL2、FMR1、FYN、GRO3、LFNG、IVNS1ABP、P125、PBEF、PRKCB1、PSCDBP、PTPRE、SCP2、TMEM2、TNF、ZFP103)尽管治疗前与正常对照组比较正常、下调或上调各不相同，但治疗后较治疗前均表现为上调。
3．对87个前、中、后三次样品具有相似性表达变化的基因数据进行了聚类分析，下调的有21个，上调的有66个。下调基因主要有免疫应答相关基因(DXS1357E、LY117、IGHG3、IGKC、IGL@、PTPRCAP)及炎症反应相关基因(LY117、ADORA3、MIF、EDG6、CTSH)，以及一些细胞凋亡增殖、信号通道及代谢相关等基因(H2AFO、RPL28、FEZ1、EMP3、CAPN4、MIF、DXS1357E、APRT、COX6A1、PLEC1、RPS5、DGKA、NMBR、PTPRCAP)。上调的基因中主要有信号转导相关基因(SHOC2、SEL1L、JAK2、NGB、BIG2、DPYSL2、RGS19、PTGS2、BAI3)，免疫炎症相关基因(ILF3、B4-2、PTPRC、KLRC1、CSF2RB、PBEF、GRO3、DAF、SDCBP、TNF、TRA1、SSFA2、HSPA9B、JAK2)，转录调控修饰相关基因(B4-2、ZNF9、RYBP、TFEC、ZNF217、SSX2、ATF3、HUMHOXY1、MAF、SMARCA5、LFNG、PTGS2、NS1-BP、EGR2、SF3B1、prpf4、GRSF1)，细胞增殖、凋亡与分化相关基因(CLK1、BTG3、IFI16、RYBP、TNF、CCNG2、ERCC5、IDN3、CLK1、CDC23)，以及生物合成、膜蛋白等(TBCC、DLEU2、ZNF217、PLSCR1、TMEM2、SCP2、CD47、CGGBP1、TACC1、DNM1、EBI2、PIGA、SLC7A6、KIAA1382、PTPRC、IPLA2、FOSB)。
4．研究发现阴虚内热证SLE患者治疗前后均有凋亡相关基因的异常表达。治疗前促进细胞凋亡的许多基因明显上调，抑制细胞凋亡的基因则多数表达下调，而治疗3个月后则出现相反的情况，证实细胞凋亡紊乱在SLE的发病中起着重要的作用，糖皮质激素配合滋阴清热方治疗可能可以从凋亡的多个环节对细胞凋亡进行调控，从而改善病情。治疗前后均下调，前后变化不大的有8个凋亡相关基因，其中抗凋亡的基因有：AIM、BLC2、BY55、HSPD1；促进细胞凋亡的有：DR6、PA26；而HUS1与ITK在细胞凋亡中起着重要的调节作用。治疗后较治疗前上调的凋亡相关基因有21个，其中抗细胞凋亡的基因有：SGK、AD022、API5、BAG1、BAG3、BCL6、SGK、VCAM1、BCL2A1、BNIP2、GG2-1、HSPA1B、IL1B、TNFRSF6、IL2RB；促进细胞凋亡的基因有：CASP3、TNF、TNFSF10，以及NKTR、HLA-DQA1、HLA-G、CD83参与体液免疫应答和信号传导等途径参与调节细胞凋亡。
5．HLA基因家族等基因有异常表达：HLA-C、HLA-DQB1、HLA-G与HLA-DPB1在SLE中以上调为主，虽然治疗后表达有所下调，但总体仍高于正常人，而HLA-B、HLA-DQA1为下调，治疗后无明显改变，HLA-E治疗后下调，但与治疗前差异无统计学意义(P=0.069)。HLA-DQB1基因可能是治疗相关基因，治疗后其对应表达的HLA-DQB1蛋白片段量减少。
7．治疗前阴虚内热证SLE患者与正常人蛋白表达存在差异：治疗前SLE患者与正常人比较，找出152个蛋白峰，其中73个峰差异有统计学意义(P＜0.05)，建立判别中药治疗前SLE患者与正常人的10542 Da m／z和2554 Da m／z蛋白质质谱检测模型，其判别率为100％，可以通过以上两个峰将SLE与正常人区别开来。10542标志物最可能是HLA基因家族相关的多个蛋白片段的复合物。2554Da m／z可能与SLE的发病密切相关，可能是一个红斑狼疮患者发病有关的未知蛋白或多肽片段，有待进一步研究证实。
8．阴虚内热证SLE患者治疗前、后蛋白表达存在差异：治疗3个月后与治疗前比较，共发现蛋白峰167个，其中20个差异有统计学意义(P＜0.05)。
结论
1．治疗后中医症候积分显著低于治疗前，滋阴清热方可以改善SLE患者的阴虚内热症状。
2．阴虚内热证SLE患者细胞凋亡相关、免疫相关等基因表达紊乱，治疗前、中、后许多基因表达有显著改变，提示滋阴清热方可能通过调节患者基因表达紊乱而达到阴平阳秘的治疗作用。对SLE及其它免疫相关疾病的进一步大样本基因聚类分析研究，可能可以建立SLE早期诊断、鉴别诊断及中医不同证候的基因表达模式。
3．阴虚内热证患者PBMC蛋白表达模式与正常人有差异，可以通过蛋白表达模式区别正常人和SLE样本，提示可以用蛋白芯片的方法实现SLE的早期诊断，有待进一步研究。
4．治疗前、中、后许多蛋白有差异表达，提示滋阴清热方可能通过调节患者PBMC蛋白表达而达到治疗作用。对发现的蛋白质荷峰标志物进一步深入研究，有可能找到治疗相关靶蛋白，值得深入研究。
Background
Systemic lupus erythematosus (SLE) as a serious autoimmune disease, theetiology, pathogenesis of this disease had not been fully explained and thetreatment are still a world's problems. Currently, corticosteroids andimmunosuppressants are the main treatments, but the application will bringlong-term significant toxicities. Clinical Practice has proved thatintegrated traditional and western medicine methods can significantly reducedrug toxicity and improve life quality of SLE patients. Internal Heat due toYin Dificiency(IHDYD) is the basic types of SLE, Nourish yin, tonify thekidney, clear away heat and suppress fire are the basic rules for the treatmentof SLE. Many studies showed that many genes take part in the onset of SLE.Study the dynamic changes of gene regulation networks and protein interactionnetwork of SLE will help us to understand the pathogenesis of SLE deeply.
Objective
Observed the Treatment Effects of Nourishing Yin Clearing Heat formula(NYCHF) on patients of SLE with Internal Heat due to Yin Oificiency(IHDYD);Studied the dynamic changes of gene and protein expression of the peripheralblood mononuclear cell (PBMC) according to three different stages: Before cure,six weeks and 12 weeks after treatment among 3 months. Try to learn thesimilarities and differences of gene and protein expression patterns betweenpatients and normal persons, explore treatment mechanism of NYCHF and prepareto establish methods and platform for Chinese medical research for SLE at thelevel of gene and protein expression.
Methods
1. Objects
Fifteen IHDYD female SLE patients were 18 to 50 years old, outpatient ofthe TCM hospital of GuangDong province of China from November 2005 to November 2006, with diagnosis as SLE according to the American Rheumatism Association1997 revised diagnostic criteria, in line with IHDYD certification standards,and in the mild or moderate activity with the score between 5 to 25 accordingto SLEDAI system of the United States and Canada SLE center. If had been usingglucocorticoids, then must maintain the dosage at 10-25 mg/day within the nextthree months study. Must withdrawal non-steroidal anti-inflammatory drug overa week and hadn't used immunosuppressant over six months. All of the casesmust finish 3 months courses of treatment and record detailed according toCase Report Form. Fifteen normal control were healthy voluntaries fromGuangzhou University of Traditional Chinese Medicine with a mean age: 28.4±6.50. Treatment group had included 18 cases, two cases exodus and one lost,15 cases were effective, with a mean age:31.60±9.37 years. The age varianceof two groups were homogeneity (P=0.098), and there were nonsignificantstatistically difference between two groups acording to two sample t test(P=0.289).
2. Treatment and observation
Patients were given five NYCHFs three times per day during three months,and score of IHDYDwere got every two weeks. C_3, C_4, anti-nuclear antibody (ANA),anti-dsDNA, blood routine, urine routine, and other indicators were detectedbefore, 6 weeks and 12 weeks after cured with NYCHF, and PBMC were extractedand stored in refrigerator at -70℃. Only samples of those cases that hadfinished three months observation were sended to gene or protein microarraychips detect. Case information was collected detailed acording to "Case ReportForm."
3. DNA microarray chip experiment
cDNA were directly pointed on chips to made the human cDNA microarray chipsby the Chipscreen Biosciences, with total genes as 8,064, probes were markedwith Cy3 single fluorescent, data were revised standardizd, Calculated theratio of gene expression in the experimental group and control group. If Ratiowas greater than 2 or less than 0.5, there were significant differences betweenthem. GeneCluster 2 software was use to analysis the data with self-organizingmaps, functional classification and clustering analysis methods.
4. Protein microarray experiment
Using Surface Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI) methods established the PBMC protein expression data ofSLE patients before treatment, six weeks, and 12 weeks after treatment andthe normal control group. ZUCIPDAS package designed by Jie-Kai Yu of CancerInstitute of Zhejiang University were used to identify the protein peaksdiscriminant model. The name and the preliminary function of the protein peakswere identified by Crosslinked compareing between Gene microarray expressiondatabase and the Expasy protein database.
Results
1. Glucocorticoid with NYCHF can relieve pathogenetic condition of IHDYDSLE quickly, soft self discomfortable sense, decrese scores of SLEDAI and IHDYDsignificantly, and incerese the level of C3 and C4. Scores between IHDYD andSLEDAI was positively correlated which suggested that Scores of IHDYD canreflect the condition of the patient fairly integratly and objectively.
2. 2,946 gene expression data were acquired by using normalized dataprocess methods. 167 genes which has marked differences expression at leastone time in three independent experiments were categoried to 25 differentpatterns and analysis the difference among three stages used the repeatmeasurements analysis of variance, the differences were statisticallysignificant (P=0.000). 20 different genes had statistically significantdifferent (P＜0.05) expression at three different test times: IGKC expressiondecreased after cure 12 weeks and lower than the expression of normal control,the expression of another 19 genes (Arp2, ARCN1, CRY2, DAF, DPYSL2, FMR1. FYN,GRO3, LFNG, IVNS1ABP, P125, PBEF, PRKCB1. PSCDBP, PTPRE, Carrier, TMEM2, TNF,ZFP103) were increased, decreased or normal in SLE than in the normal control,but compared with the expression of themself before cure, they all increasedafter treatment.
3. Genes with similar changes in the expression of three samples (before,during and after the cure) were analyzed with cluster method, and 87 geneswere clustered: 21 genes expressed decreased and 66 genes expression increasedafter cure than before cure. down expressed Gene mainly related to the immuneresponse genes (DXS1357E, LY117, IGHG3, IGKC, IGL@, PTPRCAP), inflammationrelated genes (LY117, ADORA3, MIF, EDG6, CTSH), and some cell apoptosis andproliferation, signal pathway and metabolic associate gene (H2AFO, RPL28, FEZ1, EMP3, CAPN4, MIF, DXS1357E, APRT, COXBA1, PLEC1, RPS5, DGKA, NMBR,PTPRCAP). Up-regulated expression genes mainly related to the signaltransduction genes (SHOC2, SEL1L, JAK2, NGB, BIG2, DPYSL2, RGS19, PTGS2, BAI3),immune inflammation related genes (ILF3, B4-2, PTPRC, KLRC1, CSF2RB, PBEF,GRO3, DAF, SDCBP, TNF, TRA1, SSFA2, HSPA9B, JAK2), the transcriptionalregulation of gene-modified (B4-2, ZNF9, RYBP, TFEC, ZNF217, SSX2, ATF3,HUMHOXY1, MAF, SMARCA5, LFNG, PTGS2, NS1-BP, EGR2, SF3B1, prpf4, GRSF1), cellproliferation, apoptosis and differentiation-related genes (Aug, BTG3, E6,RYBP, TNF, CCNG2, ERCC5, IDN3, CLK1, CDC23), and the biosynthesis and membraneprotein related genes (TBCC, DLEU2, ZNF217, PLSCR1, TMEM2, SCP2, CD47, CGGBP1,TACC1, DNM1, EBI2, PIGA, SLCTA6, KIAA1382, PTPRC, IPLA2, FOSB).
Conclusions
1. Score of IHDYD symptom decreased significantly along with the time oftreatment, suggesting NYCHF can improve the symptoms of IHDYD SLE patients.
2. Apoptosis, immune-related gene expression disorder were found in IHDYDSLE patients before or during treatment, Gene expression patterns changesignificantly in the three months study. NYCHF may adjust YIN and YANG in arelative equilibrium through regulates the gene expression disorder patientsand achieves treatment effect. Further study on SLE and other immune-relateddiseases use large sample gene clustering analysis may be able to establishearly diagnosis, differential diagnosis and build different gene expressionpatterns of Chinese medicine syndromes.
3. Different protein expression patterns of PBMC were observed betweenIHDYD SLE Patients and normal samples, Suggesting protein chip can be usedto build the method for early diagnosis of SLE, pending further study.
4. Many differences of protein expression observed before, during and afterthe treatment, suggesting NYCHF may cure IHDYD SLE patients by regulatingprotein expression of PBMC. Further study on the discovered protein-markermay lead to find treatment-related protein target. It is worth to depthstudying.
系统性红斑狼疮(systemic lupus erythematosus，SLE)作为一种严重危害健康的自身免疫性疾病，其病因、发病机制尚未完全阐明，治疗至今仍是世界难题。目前西医仍主要用糖皮质激素和免疫抑制剂治疗，长期应用会带来明显的毒副作用。临床实践证明中西医结合治疗SLE临床疗效突出，可减少药物的毒副作用，提高SLE患者的生存质量。阴虚内热是SLE的基本证型，滋阴清热法是治疗SLE基本法则。现代研究认为SLE的发生是由多基因共同作用的结果。研究SLE基因调控网络和蛋白质相互作用网络的动态变化将有助于我们对SLE发病的深入了解。
目的
观察滋阴清热方治疗阴虚内热证SLE的疗效，研究SLE患者治疗前、中(治疗6周)、后(治疗12周)外周血单核细胞(peripheral blood mononuclear cell，PBMC)基因及蛋白表达谱的动态改变，了解阴虚内热证SLE患者基因及蛋白表达模式与正常人间的异同，从基因及蛋白水平探讨中医药治疗机理，为构建中医药治疗SLE的基因与蛋白表达谱研究方法与平台打下基础。
方法
1．研究对象
女性阴虚内热证SLE病例来自2005年11月至2006年11月在广东省中医院门诊就诊的确诊病人，轻、中度活动(5≤SLEDAI≥25分)，如使用了糖皮质激素，则维持量为10～25mg／日，三个月内不加量，如使用过非甾体抗炎药则需停药一周以上，如使用过其它免疫抑制剂则需停药半年以上。健康对照组来自于广州中医药大学健康大学生和健康志愿者，共15例，均为女性。治疗组总共纳入18例，其中退出2例，失访1例，有效病例共15例，平均年龄：31.60±9.37；健康对照组平均年龄：28.4±6.50。两组年龄经两样本t检验，方差齐性(P=0.098)，差异无统计学意义(P=0.289)。
2．治疗与疗效观察
入选病例用滋阴清热方制成胶囊，每次5粒，每日3次口服治疗3个月，每两周进行中医症候积分评估，并在中药治疗前、治疗6周、治疗12周时评定活动度积分，检测患者血清补体C_3、C_4水平、抗核抗体(ANA)、抗双链DNA抗体(Ds-DNA)、血常规、尿常规等指标，提取PBMC总RNA和总蛋白质，-70℃保存备用，将完成3次观察的合格病例的样品进行基因芯片与蛋白芯片的检测。所有病例均按病例资料收集要求与规范详细填写《病例观察报告表》。
3．基因芯片实验与分析方法
人类基因表达谱芯片由微芯生物公司采用cDNA直接点样生产，共有8064个基因点，采用Cy3单荧光标记探针，数据经标准化校正，计算基因表达量在实验组和对照组间的比值(Ratio)，按Ratio大于2或小于0.5作为表达差异的显著性标准。运用国际通用的GeneCluster 2软件对标准化后数据进行SOMs(self-organizing maps；自组图)分析、功能分类分析和聚类分析。
4．蛋白芯片实验与分析方法
采用表面加强激光解吸电离-飞行时间质谱(SELDI)方法建立SLE患者治疗前、治疗6周、治疗12周以及正常对照组PBMC蛋白质表达数据，利用浙江大学肿瘤研究所余捷凯等研究设计的ZUCIPDAS软件包找出蛋白质荷峰，建立判别模型，采用基因芯片表达数据库与Expasy蛋白数据库交连比对分析方法初步确定蛋白质荷峰的可能名称与功能。
结果
1．糖皮质激素配合滋阴清热方治疗可以较快缓解阴虚内热证SLE患者病情，改善自觉症状，SLEDAI积分、中医症候积分治疗后显著下降，C_3、C_4水平上升，患者病情有明显改善。中医症候积分与SLEDAI积分呈正相关，提示中医症候评分可以较客观地综合反映患者的病情。
2．经归一化等数据处理后得到2946个基因表达数据。对其中至少三次独立实验处理过程中存在明显的表达差异的数据进行自组图分析分为25类共167个基因，3次表达经重复测量数据的方差分析，差异有显著性意义(P=0.000)，其中有20个基因前后比较差异有统计学意义(P＜0.05)：其中人免疫球蛋白K链c区(IGKC)基因，治疗后下调，低于正常人，其余19个基因(Arp2、ARCN1、CRY2、DAF、DPYSL2、FMR1、FYN、GRO3、LFNG、IVNS1ABP、P125、PBEF、PRKCB1、PSCDBP、PTPRE、SCP2、TMEM2、TNF、ZFP103)尽管治疗前与正常对照组比较正常、下调或上调各不相同，但治疗后较治疗前均表现为上调。
3．对87个前、中、后三次样品具有相似性表达变化的基因数据进行了聚类分析，下调的有21个，上调的有66个。下调基因主要有免疫应答相关基因(DXS1357E、LY117、IGHG3、IGKC、IGL@、PTPRCAP)及炎症反应相关基因(LY117、ADORA3、MIF、EDG6、CTSH)，以及一些细胞凋亡增殖、信号通道及代谢相关等基因(H2AFO、RPL28、FEZ1、EMP3、CAPN4、MIF、DXS1357E、APRT、COX6A1、PLEC1、RPS5、DGKA、NMBR、PTPRCAP)。上调的基因中主要有信号转导相关基因(SHOC2、SEL1L、JAK2、NGB、BIG2、DPYSL2、RGS19、PTGS2、BAI3)，免疫炎症相关基因(ILF3、B4-2、PTPRC、KLRC1、CSF2RB、PBEF、GRO3、DAF、SDCBP、TNF、TRA1、SSFA2、HSPA9B、JAK2)，转录调控修饰相关基因(B4-2、ZNF9、RYBP、TFEC、ZNF217、SSX2、ATF3、HUMHOXY1、MAF、SMARCA5、LFNG、PTGS2、NS1-BP、EGR2、SF3B1、prpf4、GRSF1)，细胞增殖、凋亡与分化相关基因(CLK1、BTG3、IFI16、RYBP、TNF、CCNG2、ERCC5、IDN3、CLK1、CDC23)，以及生物合成、膜蛋白等(TBCC、DLEU2、ZNF217、PLSCR1、TMEM2、SCP2、CD47、CGGBP1、TACC1、DNM1、EBI2、PIGA、SLC7A6、KIAA1382、PTPRC、IPLA2、FOSB)。
4．研究发现阴虚内热证SLE患者治疗前后均有凋亡相关基因的异常表达。治疗前促进细胞凋亡的许多基因明显上调，抑制细胞凋亡的基因则多数表达下调，而治疗3个月后则出现相反的情况，证实细胞凋亡紊乱在SLE的发病中起着重要的作用，糖皮质激素配合滋阴清热方治疗可能可以从凋亡的多个环节对细胞凋亡进行调控，从而改善病情。治疗前后均下调，前后变化不大的有8个凋亡相关基因，其中抗凋亡的基因有：AIM、BLC2、BY55、HSPD1；促进细胞凋亡的有：DR6、PA26；而HUS1与ITK在细胞凋亡中起着重要的调节作用。治疗后较治疗前上调的凋亡相关基因有21个，其中抗细胞凋亡的基因有：SGK、AD022、API5、BAG1、BAG3、BCL6、SGK、VCAM1、BCL2A1、BNIP2、GG2-1、HSPA1B、IL1B、TNFRSF6、IL2RB；促进细胞凋亡的基因有：CASP3、TNF、TNFSF10，以及NKTR、HLA-DQA1、HLA-G、CD83参与体液免疫应答和信号传导等途径参与调节细胞凋亡。
5．HLA基因家族等基因有异常表达：HLA-C、HLA-DQB1、HLA-G与HLA-DPB1在SLE中以上调为主，虽然治疗后表达有所下调，但总体仍高于正常人，而HLA-B、HLA-DQA1为下调，治疗后无明显改变，HLA-E治疗后下调，但与治疗前差异无统计学意义(P=0.069)。HLA-DQB1基因可能是治疗相关基因，治疗后其对应表达的HLA-DQB1蛋白片段量减少。
7．治疗前阴虚内热证SLE患者与正常人蛋白表达存在差异：治疗前SLE患者与正常人比较，找出152个蛋白峰，其中73个峰差异有统计学意义(P＜0.05)，建立判别中药治疗前SLE患者与正常人的10542 Da m／z和2554 Da m／z蛋白质质谱检测模型，其判别率为100％，可以通过以上两个峰将SLE与正常人区别开来。10542标志物最可能是HLA基因家族相关的多个蛋白片段的复合物。2554Da m／z可能与SLE的发病密切相关，可能是一个红斑狼疮患者发病有关的未知蛋白或多肽片段，有待进一步研究证实。
8．阴虚内热证SLE患者治疗前、后蛋白表达存在差异：治疗3个月后与治疗前比较，共发现蛋白峰167个，其中20个差异有统计学意义(P＜0.05)。
结论
1．治疗后中医症候积分显著低于治疗前，滋阴清热方可以改善SLE患者的阴虚内热症状。
2．阴虚内热证SLE患者细胞凋亡相关、免疫相关等基因表达紊乱，治疗前、中、后许多基因表达有显著改变，提示滋阴清热方可能通过调节患者基因表达紊乱而达到阴平阳秘的治疗作用。对SLE及其它免疫相关疾病的进一步大样本基因聚类分析研究，可能可以建立SLE早期诊断、鉴别诊断及中医不同证候的基因表达模式。
3．阴虚内热证患者PBMC蛋白表达模式与正常人有差异，可以通过蛋白表达模式区别正常人和SLE样本，提示可以用蛋白芯片的方法实现SLE的早期诊断，有待进一步研究。
4．治疗前、中、后许多蛋白有差异表达，提示滋阴清热方可能通过调节患者PBMC蛋白表达而达到治疗作用。对发现的蛋白质荷峰标志物进一步深入研究，有可能找到治疗相关靶蛋白，值得深入研究。
Background
Systemic lupus erythematosus (SLE) as a serious autoimmune disease, theetiology, pathogenesis of this disease had not been fully explained and thetreatment are still a world's problems. Currently, corticosteroids andimmunosuppressants are the main treatments, but the application will bringlong-term significant toxicities. Clinical Practice has proved thatintegrated traditional and western medicine methods can significantly reducedrug toxicity and improve life quality of SLE patients. Internal Heat due toYin Dificiency(IHDYD) is the basic types of SLE, Nourish yin, tonify thekidney, clear away heat and suppress fire are the basic rules for the treatmentof SLE. Many studies showed that many genes take part in the onset of SLE.Study the dynamic changes of gene regulation networks and protein interactionnetwork of SLE will help us to understand the pathogenesis of SLE deeply.
Objective
Observed the Treatment Effects of Nourishing Yin Clearing Heat formula(NYCHF) on patients of SLE with Internal Heat due to Yin Oificiency(IHDYD);Studied the dynamic changes of gene and protein expression of the peripheralblood mononuclear cell (PBMC) according to three different stages: Before cure,six weeks and 12 weeks after treatment among 3 months. Try to learn thesimilarities and differences of gene and protein expression patterns betweenpatients and normal persons, explore treatment mechanism of NYCHF and prepareto establish methods and platform for Chinese medical research for SLE at thelevel of gene and protein expression.
Methods
1. Objects
Fifteen IHDYD female SLE patients were 18 to 50 years old, outpatient ofthe TCM hospital of GuangDong province of China from November 2005 to November 2006, with diagnosis as SLE according to the American Rheumatism Association1997 revised diagnostic criteria, in line with IHDYD certification standards,and in the mild or moderate activity with the score between 5 to 25 accordingto SLEDAI system of the United States and Canada SLE center. If had been usingglucocorticoids, then must maintain the dosage at 10-25 mg/day within the nextthree months study. Must withdrawal non-steroidal anti-inflammatory drug overa week and hadn't used immunosuppressant over six months. All of the casesmust finish 3 months courses of treatment and record detailed according toCase Report Form. Fifteen normal control were healthy voluntaries fromGuangzhou University of Traditional Chinese Medicine with a mean age: 28.4±6.50. Treatment group had included 18 cases, two cases exodus and one lost,15 cases were effective, with a mean age:31.60±9.37 years. The age varianceof two groups were homogeneity (P=0.098), and there were nonsignificantstatistically difference between two groups acording to two sample t test(P=0.289).
2. Treatment and observation
Patients were given five NYCHFs three times per day during three months,and score of IHDYDwere got every two weeks. C_3, C_4, anti-nuclear antibody (ANA),anti-dsDNA, blood routine, urine routine, and other indicators were detectedbefore, 6 weeks and 12 weeks after cured with NYCHF, and PBMC were extractedand stored in refrigerator at -70℃. Only samples of those cases that hadfinished three months observation were sended to gene or protein microarraychips detect. Case information was collected detailed acording to "Case ReportForm."
3. DNA microarray chip experiment
cDNA were directly pointed on chips to made the human cDNA microarray chipsby the Chipscreen Biosciences, with total genes as 8,064, probes were markedwith Cy3 single fluorescent, data were revised standardizd, Calculated theratio of gene expression in the experimental group and control group. If Ratiowas greater than 2 or less than 0.5, there were significant differences betweenthem. GeneCluster 2 software was use to analysis the data with self-organizingmaps, functional classification and clustering analysis methods.
4. Protein microarray experiment
Using Surface Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI) methods established the PBMC protein expression data ofSLE patients before treatment, six weeks, and 12 weeks after treatment andthe normal control group. ZUCIPDAS package designed by Jie-Kai Yu of CancerInstitute of Zhejiang University were used to identify the protein peaksdiscriminant model. The name and the preliminary function of the protein peakswere identified by Crosslinked compareing between Gene microarray expressiondatabase and the Expasy protein database.
Results
1. Glucocorticoid with NYCHF can relieve pathogenetic condition of IHDYDSLE quickly, soft self discomfortable sense, decrese scores of SLEDAI and IHDYDsignificantly, and incerese the level of C3 and C4. Scores between IHDYD andSLEDAI was positively correlated which suggested that Scores of IHDYD canreflect the condition of the patient fairly integratly and objectively.
2. 2,946 gene expression data were acquired by using normalized dataprocess methods. 167 genes which has marked differences expression at leastone time in three independent experiments were categoried to 25 differentpatterns and analysis the difference among three stages used the repeatmeasurements analysis of variance, the differences were statisticallysignificant (P=0.000). 20 different genes had statistically significantdifferent (P＜0.05) expression at three different test times: IGKC expressiondecreased after cure 12 weeks and lower than the expression of normal control,the expression of another 19 genes (Arp2, ARCN1, CRY2, DAF, DPYSL2, FMR1. FYN,GRO3, LFNG, IVNS1ABP, P125, PBEF, PRKCB1. PSCDBP, PTPRE, Carrier, TMEM2, TNF,ZFP103) were increased, decreased or normal in SLE than in the normal control,but compared with the expression of themself before cure, they all increasedafter treatment.
3. Genes with similar changes in the expression of three samples (before,during and after the cure) were analyzed with cluster method, and 87 geneswere clustered: 21 genes expressed decreased and 66 genes expression increasedafter cure than before cure. down expressed Gene mainly related to the immuneresponse genes (DXS1357E, LY117, IGHG3, IGKC, IGL@, PTPRCAP), inflammationrelated genes (LY117, ADORA3, MIF, EDG6, CTSH), and some cell apoptosis andproliferation, signal pathway and metabolic associate gene (H2AFO, RPL28, FEZ1, EMP3, CAPN4, MIF, DXS1357E, APRT, COXBA1, PLEC1, RPS5, DGKA, NMBR,PTPRCAP). Up-regulated expression genes mainly related to the signaltransduction genes (SHOC2, SEL1L, JAK2, NGB, BIG2, DPYSL2, RGS19, PTGS2, BAI3),immune inflammation related genes (ILF3, B4-2, PTPRC, KLRC1, CSF2RB, PBEF,GRO3, DAF, SDCBP, TNF, TRA1, SSFA2, HSPA9B, JAK2), the transcriptionalregulation of gene-modified (B4-2, ZNF9, RYBP, TFEC, ZNF217, SSX2, ATF3,HUMHOXY1, MAF, SMARCA5, LFNG, PTGS2, NS1-BP, EGR2, SF3B1, prpf4, GRSF1), cellproliferation, apoptosis and differentiation-related genes (Aug, BTG3, E6,RYBP, TNF, CCNG2, ERCC5, IDN3, CLK1, CDC23), and the biosynthesis and membraneprotein related genes (TBCC, DLEU2, ZNF217, PLSCR1, TMEM2, SCP2, CD47, CGGBP1,TACC1, DNM1, EBI2, PIGA, SLCTA6, KIAA1382, PTPRC, IPLA2, FOSB).
Conclusions
1. Score of IHDYD symptom decreased significantly along with the time oftreatment, suggesting NYCHF can improve the symptoms of IHDYD SLE patients.
2. Apoptosis, immune-related gene expression disorder were found in IHDYDSLE patients before or during treatment, Gene expression patterns changesignificantly in the three months study. NYCHF may adjust YIN and YANG in arelative equilibrium through regulates the gene expression disorder patientsand achieves treatment effect. Further study on SLE and other immune-relateddiseases use large sample gene clustering analysis may be able to establishearly diagnosis, differential diagnosis and build different gene expressionpatterns of Chinese medicine syndromes.
3. Different protein expression patterns of PBMC were observed betweenIHDYD SLE Patients and normal samples, Suggesting protein chip can be usedto build the method for early diagnosis of SLE, pending further study.
4. Many differences of protein expression observed before, during and afterthe treatment, suggesting NYCHF may cure IHDYD SLE patients by regulatingprotein expression of PBMC. Further study on the discovered protein-markermay lead to find treatment-related protein target. It is worth to depthstudying.
引文
[1] 周渭珩，程东庆，洪为松，等．血清可溶性黏附分子与系统性红斑狼疮患者活动性的关系．中华皮肤科杂志，2005，38(1)：17-19
[2] 朱铭华，卢植生，黄述江，等．系统性红斑狼疮辨证分型与可溶性粘附分子之间关系探讨．广州中医药大学学报，2004，21(4)：247-249
[3] 刘新霞，周毅．性激素在系统性红斑狼疮发病机制中的研究进展．广州医药，2004，35(3)：2-5
[4] 颜耀斌，陈东成．系统性红斑狼疮中医分型与性激素水平的关系．福建中医药，1997，8(1)：8
[5] 周倩宜，齐文，成韩锋．SLE患者PBMCs雌激素受体mRNA水平与IL-10mRNA水平的研究．天津医药，2005，33(11)：694-696
[6] 张京玲，倪春生，陈宏，等．疏肝活血法对SLE小鼠皮肤雌激素受体的作用．天津医药，2006，(9)：631-632
[7] 杨爱国，阮诗玮，郑弘义，等．系统性红斑狼疮活动期患者尿表皮生长因子与中医辨证分型的关系．中医药研究，1999，15(3)：17
[8] 范永升，陈湘君．系统性红斑狼疮中医药研究新进展．浙江中医学院学报，2004，28(3)：73-76
[9] 吴元胜，范瑞强，陈红．禤国维教授论治系统性红斑狼疮经验举要．广州中医药大学学报，2003，20(3)：246-248
[10] 查旭山，范瑞强．禤国维教授中西医结合治疗系统性红斑狼疮32例．新中医，2001，33(8)：31—32
[11] 徐安平，尹培达．中国南方系统性红斑狼疮患者Fas-670基因多态性研究．中国病理生理杂志，2004，20(10)：1819—1822
[12] 陈兴国，池淑红，顾越英，等．系统性红斑狼疮相关基因IFIT1的功能初探．中华风湿病学杂志，2004，8(7)：395—399
[13] 姜福琼，李学平，杨红英，等．67例云南汉族FcCRA基因多态性分布与SLE易感性的研究．皮肤病与性病，2005，27(1)：1-4
[14] Pan F, Zhang K, Li X, et al. Association of Fc gamma receptor IIB gene polymorphism with genetic susceptibility to systemic lupus erythematosus in Chinese populations-a family-based association study. J Dermatol Sci. 2006 Jul; 43(1): 35-41.
[15] 冯学兵，沈南，叶霜，等．中国人群16号染色体q12区存在系统性红斑狼疮易感基因．中华医学遗传学杂志，2003，20(1)：27-30
[16] 吴元胜，范瑞强，陈达灿，等．不同证型系统性红斑狼疮患者外周血基因表达谱差异初探．广州中医药大学学报，2004，21(4)：241-246
[17] 韩光明，叶霜，沈南．外周血基因表达谱的初步研究．中华风湿病学杂志，2002，6(6)：392-396
[18] Rus V, Atamas SP, Shustova V, et al. Expression of cytokine and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol, 2002, 102(3): 283
[19] Han GM, Chen SL, Shen N, et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun, 2003, 4(3): 177
[20] 叶霜，沈南，顾越英，等．系统性红斑狼疮的基因表达谱及其免疫调控通路的研究．中华风湿病学杂志，2002，6(6)：411-416
[21] 朱方石．SLE辨证分型论治现状的分析与思考．江苏中医，2001，22(8)：6-7
[22] 吴元胜，范瑞强，黄泳菁．禤国维教授系统性红斑狼疮辨治观浅析．中国中医药信息，2003，10(5)：69-70
[23] 吴元胜，范瑞强，陈红，等．基因芯片技术分析SLE证候基因表达的初步研究．现代中西医结合杂志 2003，12(16)：1683
[24] 黄成，樊嘉．蛋白质芯片SELDI-TOF-MS技术在肿瘤学研究中的应用．国外医学肿瘤学分册，2004，31(6)：434—437
[25] 吴登龙，王文静，关明，等．表面增强激光解吸离子化质谱蛋白质芯片技术在筛选肾癌患者尿液标记物中的应用．中华医学杂志，2004，24(13)：1092—1095
[26] 李倩，廖尚英，杨桂兰，等．SELDI-TOFMS技术及其在癌症早期诊断中的应用．生物技术通报，2004，(2)：41—44
[27] Jacobs JM, Mottaz HM, Yu LR, et al. Multidimensional proteome analysis of human mammary epithelial cell. J Proteome Res, 2004, 3(1): 68-75
[28] Olsen JV, Andersen JR, Nielsen PA, et al. HysTag-A Novel Proteomic Quantification Tool Applied to Differential Display Analysis of Membrane Proteins From Distinct Areas of Mouse Brain. Molecular & Cellular Proteomics, 2004 Jan; 3(1): 82-92
[29] 王家祥，张波，余捷凯，等．基于人工神经网络的血清蛋白质指纹图谱模型在肝癌诊断中的应用．中华医学杂志，2005，85(3)：189-192
[30] 张丰强，李岩，李晓锐，等．现代中药临床手册．上海科学普及出版社，1996年10月第1版。
[31] 孙保东，沈南，裴军，等．SLE病人外周血白细胞Bcl22和Bcl2XmRNA表达研究．上海免疫学杂志，2000，20(4)：239、240、247
[32] 田伟，李立新，郭实士．湖南汉族群体HLA2DR2等位基因多态性与系统性红斑狼疮的相关性研究．湖南医科大学学报，2000，25(1)：15-17
[33] 林岷格，郑少江．COX-2在系统性红斑狼疮病人PBMC中的表达及意义．中国热带医学，2004，4(4)：525-526
[34] 叶霜，庞海，顾越英，等．利用谷胱甘肽S转移酶表达标签捕获系统性红斑狼疮相关基因IFIT1的相互作用蛋白质．中华医学杂志，2003，83(9)：70-773
[35] 王红，张杏书，丁从珠．系统性红斑狼疮患者外周血淋巴细胞凋亡的临床研究．中华风湿病学杂志，2001，5(1)：52
[36] 张丽霞，郑京，洪江淮．热毒炽盛型SLE与肾小球Fas、BcL-2、Bax蛋白表达．中医药学刊，2003，21(9)：1518-1519
[37] 朱筱娟，曾宪录，宋朝霞，等．细胞核内肌动蛋白及其功能研究进展．科学通报，2004，49(11)：1031—1035
[38] 王展，曾凡钦．系统性红斑狼疮患者血和尿DNase Ⅰ与肌动蛋白的相关性研究．中华皮肤科杂志，2003，36(11)：623-625
[39] 冯学兵，沈南，陈顺乐，等．系统性红斑狼疮患者脱氧核糖核酸酶1基因表达研究．中华医学遗传学杂志，2003，20(6)：477-481
[40] Griffin EA Jr, Staknis D, Weitz CJ. Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science, 1999 Oct 22; 286(5440):768-71.
[41] Arora M, Arora R, Tiwari SC, et al. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus. 2000, 9(2):127-31
[42] Zhao X, Tang R, Xiao Z, et al. An investigation of the dihydropyrimidinase-like 2 (DPYSL2) gene in schizophrenia: genetic association study and expression analysis. Int J Neuropsychopharmacol. 2006, 9(6):705-12.
[43] Hong LE, Wonodi I, Avila MT, et al. Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2005, 136(1):8-11
[44] 滕振平，邢飞跃，于哲，等．Jagged1在树突状细胞诱导免疫耐受中的作用．细胞生物学杂志，2006，28(4)：535-538
[45] Wolff T, O'eill RE, Palese P. NSl-binding protein (NS1-BP): a novel human protein that interacts with the influenza A virus nonstructural NS1 protein is relocalized in the nuclei of infected cells [J]. J Viro, 1998, 72: 7170-7180.
[46] Tosbihide Mizoguchi, Ken-ichi Nakajima, Kiyotaka Batsuzawa, et al. Determination of Functional Regions of p125, a Novel Mammalian Sec23p-Interacting Protein. Biochemical and Biophysical Research Communications, 2000, 279(1), 144- 149
[47] Nowell MA, Richards PJ, Fielding CA, et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum, 2006, 54(7):2084-95
[48] Araki S, Haneda M, Sugimoto T, et al. Polymorphisms of the protein kinase C-beta gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria. Diabetes Care, 2006, 29(4):864-8.
[49] 汤蕾，杜芳腾，张吉翔．受体型蛋白酪氨酸磷酸酶O的研究进展．医学分子生物学杂志，2005，2(4)：278-280
[50] 龚非力主编．医学免疫学．科学出版社，2000年6月第一版
[51] Nishioka G, Yamada M, Kudo K, et al. Induction of kf-1 after repeated electroconvulsive treatment and chronic antidepressant treatment in rat frontal cortex and hippocampus. J Neural Transm, 2003, 110(3):277-85
[52] Wei Wu, Shamita Chaudhuri, Deanna R. Bfickley, et al. Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells. Cancer Res. 2004 Mar 1;64(5):1757-64.
[53] 王惠琳，郝飞，游弋，等．γ干扰素诱导蛋白30基因在系统性红斑狼疮CD4~+T细胞中的表达分析．第三军医大学学报，2006，28(9)：919-921
[54] 叶冬青，陆伟，李向培．系统性红斑狼疮HLA2DM基因与环境危险因素研究．中国卫生统计，2004，21(5)：300-302、281
[55] 周倩宜，齐文成，韩锋，等．SLE患者PBMCs雌激素受体mRNA水平与IL-10mRNA水平的研究．天津医药，2005(11)：694-696
[56] 吴志华主编．现代皮肤性病学．广东人民出版社，2000年1月第一版
[2] 朱铭华，卢植生，黄述江，等．系统性红斑狼疮辨证分型与可溶性粘附分子之间关系探讨．广州中医药大学学报，2004，21(4)：247-249
[3] 刘新霞，周毅．性激素在系统性红斑狼疮发病机制中的研究进展．广州医药，2004，35(3)：2-5
[4] 颜耀斌，陈东成．系统性红斑狼疮中医分型与性激素水平的关系．福建中医药，1997，8(1)：8
[5] 周倩宜，齐文，成韩锋．SLE患者PBMCs雌激素受体mRNA水平与IL-10mRNA水平的研究．天津医药，2005，33(11)：694-696
[6] 张京玲，倪春生，陈宏，等．疏肝活血法对SLE小鼠皮肤雌激素受体的作用．天津医药，2006，(9)：631-632
[7] 杨爱国，阮诗玮，郑弘义，等．系统性红斑狼疮活动期患者尿表皮生长因子与中医辨证分型的关系．中医药研究，1999，15(3)：17
[8] 范永升，陈湘君．系统性红斑狼疮中医药研究新进展．浙江中医学院学报，2004，28(3)：73-76
[9] 吴元胜，范瑞强，陈红．禤国维教授论治系统性红斑狼疮经验举要．广州中医药大学学报，2003，20(3)：246-248
[10] 查旭山，范瑞强．禤国维教授中西医结合治疗系统性红斑狼疮32例．新中医，2001，33(8)：31—32
[11] 徐安平，尹培达．中国南方系统性红斑狼疮患者Fas-670基因多态性研究．中国病理生理杂志，2004，20(10)：1819—1822
[12] 陈兴国，池淑红，顾越英，等．系统性红斑狼疮相关基因IFIT1的功能初探．中华风湿病学杂志，2004，8(7)：395—399
[13] 姜福琼，李学平，杨红英，等．67例云南汉族FcCRA基因多态性分布与SLE易感性的研究．皮肤病与性病，2005，27(1)：1-4
[14] Pan F, Zhang K, Li X, et al. Association of Fc gamma receptor IIB gene polymorphism with genetic susceptibility to systemic lupus erythematosus in Chinese populations-a family-based association study. J Dermatol Sci. 2006 Jul; 43(1): 35-41.
[15] 冯学兵，沈南，叶霜，等．中国人群16号染色体q12区存在系统性红斑狼疮易感基因．中华医学遗传学杂志，2003，20(1)：27-30
[16] 吴元胜，范瑞强，陈达灿，等．不同证型系统性红斑狼疮患者外周血基因表达谱差异初探．广州中医药大学学报，2004，21(4)：241-246
[17] 韩光明，叶霜，沈南．外周血基因表达谱的初步研究．中华风湿病学杂志，2002，6(6)：392-396
[18] Rus V, Atamas SP, Shustova V, et al. Expression of cytokine and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol, 2002, 102(3): 283
[19] Han GM, Chen SL, Shen N, et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun, 2003, 4(3): 177
[20] 叶霜，沈南，顾越英，等．系统性红斑狼疮的基因表达谱及其免疫调控通路的研究．中华风湿病学杂志，2002，6(6)：411-416
[21] 朱方石．SLE辨证分型论治现状的分析与思考．江苏中医，2001，22(8)：6-7
[22] 吴元胜，范瑞强，黄泳菁．禤国维教授系统性红斑狼疮辨治观浅析．中国中医药信息，2003，10(5)：69-70
[23] 吴元胜，范瑞强，陈红，等．基因芯片技术分析SLE证候基因表达的初步研究．现代中西医结合杂志 2003，12(16)：1683
[24] 黄成，樊嘉．蛋白质芯片SELDI-TOF-MS技术在肿瘤学研究中的应用．国外医学肿瘤学分册，2004，31(6)：434—437
[25] 吴登龙，王文静，关明，等．表面增强激光解吸离子化质谱蛋白质芯片技术在筛选肾癌患者尿液标记物中的应用．中华医学杂志，2004，24(13)：1092—1095
[26] 李倩，廖尚英，杨桂兰，等．SELDI-TOFMS技术及其在癌症早期诊断中的应用．生物技术通报，2004，(2)：41—44
[27] Jacobs JM, Mottaz HM, Yu LR, et al. Multidimensional proteome analysis of human mammary epithelial cell. J Proteome Res, 2004, 3(1): 68-75
[28] Olsen JV, Andersen JR, Nielsen PA, et al. HysTag-A Novel Proteomic Quantification Tool Applied to Differential Display Analysis of Membrane Proteins From Distinct Areas of Mouse Brain. Molecular & Cellular Proteomics, 2004 Jan; 3(1): 82-92
[29] 王家祥，张波，余捷凯，等．基于人工神经网络的血清蛋白质指纹图谱模型在肝癌诊断中的应用．中华医学杂志，2005，85(3)：189-192
[30] 张丰强，李岩，李晓锐，等．现代中药临床手册．上海科学普及出版社，1996年10月第1版。
[31] 孙保东，沈南，裴军，等．SLE病人外周血白细胞Bcl22和Bcl2XmRNA表达研究．上海免疫学杂志，2000，20(4)：239、240、247
[32] 田伟，李立新，郭实士．湖南汉族群体HLA2DR2等位基因多态性与系统性红斑狼疮的相关性研究．湖南医科大学学报，2000，25(1)：15-17
[33] 林岷格，郑少江．COX-2在系统性红斑狼疮病人PBMC中的表达及意义．中国热带医学，2004，4(4)：525-526
[34] 叶霜，庞海，顾越英，等．利用谷胱甘肽S转移酶表达标签捕获系统性红斑狼疮相关基因IFIT1的相互作用蛋白质．中华医学杂志，2003，83(9)：70-773
[35] 王红，张杏书，丁从珠．系统性红斑狼疮患者外周血淋巴细胞凋亡的临床研究．中华风湿病学杂志，2001，5(1)：52
[36] 张丽霞，郑京，洪江淮．热毒炽盛型SLE与肾小球Fas、BcL-2、Bax蛋白表达．中医药学刊，2003，21(9)：1518-1519
[37] 朱筱娟，曾宪录，宋朝霞，等．细胞核内肌动蛋白及其功能研究进展．科学通报，2004，49(11)：1031—1035
[38] 王展，曾凡钦．系统性红斑狼疮患者血和尿DNase Ⅰ与肌动蛋白的相关性研究．中华皮肤科杂志，2003，36(11)：623-625
[39] 冯学兵，沈南，陈顺乐，等．系统性红斑狼疮患者脱氧核糖核酸酶1基因表达研究．中华医学遗传学杂志，2003，20(6)：477-481
[40] Griffin EA Jr, Staknis D, Weitz CJ. Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science, 1999 Oct 22; 286(5440):768-71.
[41] Arora M, Arora R, Tiwari SC, et al. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus. 2000, 9(2):127-31
[42] Zhao X, Tang R, Xiao Z, et al. An investigation of the dihydropyrimidinase-like 2 (DPYSL2) gene in schizophrenia: genetic association study and expression analysis. Int J Neuropsychopharmacol. 2006, 9(6):705-12.
[43] Hong LE, Wonodi I, Avila MT, et al. Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2005, 136(1):8-11
[44] 滕振平，邢飞跃，于哲，等．Jagged1在树突状细胞诱导免疫耐受中的作用．细胞生物学杂志，2006，28(4)：535-538
[45] Wolff T, O'eill RE, Palese P. NSl-binding protein (NS1-BP): a novel human protein that interacts with the influenza A virus nonstructural NS1 protein is relocalized in the nuclei of infected cells [J]. J Viro, 1998, 72: 7170-7180.
[46] Tosbihide Mizoguchi, Ken-ichi Nakajima, Kiyotaka Batsuzawa, et al. Determination of Functional Regions of p125, a Novel Mammalian Sec23p-Interacting Protein. Biochemical and Biophysical Research Communications, 2000, 279(1), 144- 149
[47] Nowell MA, Richards PJ, Fielding CA, et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum, 2006, 54(7):2084-95
[48] Araki S, Haneda M, Sugimoto T, et al. Polymorphisms of the protein kinase C-beta gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria. Diabetes Care, 2006, 29(4):864-8.
[49] 汤蕾，杜芳腾，张吉翔．受体型蛋白酪氨酸磷酸酶O的研究进展．医学分子生物学杂志，2005，2(4)：278-280
[50] 龚非力主编．医学免疫学．科学出版社，2000年6月第一版
[51] Nishioka G, Yamada M, Kudo K, et al. Induction of kf-1 after repeated electroconvulsive treatment and chronic antidepressant treatment in rat frontal cortex and hippocampus. J Neural Transm, 2003, 110(3):277-85
[52] Wei Wu, Shamita Chaudhuri, Deanna R. Bfickley, et al. Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells. Cancer Res. 2004 Mar 1;64(5):1757-64.
[53] 王惠琳，郝飞，游弋，等．γ干扰素诱导蛋白30基因在系统性红斑狼疮CD4~+T细胞中的表达分析．第三军医大学学报，2006，28(9)：919-921
[54] 叶冬青，陆伟，李向培．系统性红斑狼疮HLA2DM基因与环境危险因素研究．中国卫生统计，2004，21(5)：300-302、281
[55] 周倩宜，齐文成，韩锋，等．SLE患者PBMCs雌激素受体mRNA水平与IL-10mRNA水平的研究．天津医药，2005(11)：694-696
[56] 吴志华主编．现代皮肤性病学．广东人民出版社，2000年1月第一版